CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 33.56×, higher than 95% of its Biotechnology peers (median 5.71×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
572.11MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.50xvs all stocks
52-Week Change
12.30%vs all stocks
Market Capitalization
572.11MUSDvs all stocks (USD)
Enterprise Value
438.02MUSDvs all stocks (USD)
Forward P/E
-44.49xvs Biotechnology peers
Price to Book (MRQ)
4.37xvs Biotechnology peers
Enterprise to EBITDA
-26.22xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-14.64%vs Biotechnology peers
Return on Equity (TTM)
-19.50%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-17.84MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-12.18MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-6.10MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-16.70MUSDvs all stocks (USD)
Pre-tax Income
-13.72MUSDFY2025 · Dec 31, 2025Net Income
-13.72MUSDFY2025 · Dec 31, 2025EBIT
-16.70MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-16.70MUSDFY2025 · Dec 31, 2025Research & Development
9.90MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
6.80MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.99MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.85USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.85USDFY2025 · Dec 31, 2025Basic Shares Outstanding
7.41MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
7.41MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-13.72MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-8.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
61.83MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-13.72MUSDFY2025 · Dec 31, 2025Stock-based Compensation
4.84MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
388.22KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
5.97KUSDFY2025 · Dec 31, 2025Purchase of Investments
-87.15MUSDFY2025 · Dec 31, 2025Sale of Investments
23.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-63.45MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-35.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.13MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
91.01MUSDFY2025 · Dec 31, 2025Shares Outstanding
6.71MSharesUpdated Sep 28, 2026Float Shares
4.48MSharesUpdated Sep 28, 2026Shares Short
844.23KSharesUpdated Sep 28, 2026Short Ratio
5.38daysvs all stocks
Short % of Shares Outstanding
18.41%vs all stocks
% Held by Insiders
23.37%vs all stocks
% Held by Institutions
95.01%vs all stocks
Total Cash (MRQ)
134.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
20.01USDUpdated Sep 28, 2026Total Debt (MRQ)
205.66KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0016xvs Biotechnology peers
Current Ratio (MRQ)
33.56xvs Biotechnology peers
Book Value per Share (MRQ)
19.50USDUpdated Sep 28, 2026Total Assets
140.72MUSDvs all stocks (USD)
Total Current Assets
140.46MUSDFY2025 · Dec 31, 2025Total Liabilities
2.89MUSDFY2025 · Dec 31, 2025Total Non-current Assets
254.92KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
154.92KUSDFY2025 · Dec 31, 2025Total Current Liabilities
2.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
61.83MUSDFY2025 · Dec 31, 2025Other Short-term Investments
78.57MUSDFY2025 · Dec 31, 2025Accounts Payable
2.74MUSDFY2025 · Dec 31, 2025Long-term Debt
154.92KUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.69KUSDFY2025 · Dec 31, 2025Retained Earnings
-89.51MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
137.83MUSDvs all stocks (USD)
52-Week Low
50.07USDUpdated Sep 28, 202652-Week High
124.82USDUpdated Sep 28, 202652-Week Change
12.30%vs all stocks
Beta
1.50xvs all stocks
50-Day MA
110.55USDUpdated Sep 28, 2026200-Day MA
76.32USDUpdated Sep 28, 2026Avg 10-Day Volume
155.06KSharesUpdated Sep 28, 2026Avg 30-Day Volume
160.01KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.20USDUpdated Sep 28, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 33.56×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 33.56Industry median: 5.71Industry P95: 22.21Peers compared: 260
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ChemoCentryx Inc
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Sunflower Great Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zeria Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Starry Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Lingda Group Co., Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Xinjiang Machinery Research Institute Co., Ltd.
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Beijing Thunisoft Corporation Limited
3 interpretationsLow-Leverage Liquidity ConfigurationLiquidity Ratios ElevatedCash Elevated Relative to Current Liabilities and Total Assets